Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Pacira BioSciences announced second-quarter 2026 financial results for the period ended June 30, 2026.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pacira BioSciences announced second-quarter 2026 financial results for the period ended June 30, 2026
- Results press release issued August 4, 2026, with full financial details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $192.4M, up 6%, led by EXPAREL sales of $147.8M, up 3% despite discounting pressure
- GAAP net income $4.7M versus $4.8M loss, while adjusted EBITDA declined to $48.7M from $54.3M
- iovera° divestiture closed July 31 for $73.6M cash, with potential proceeds up to $140M through 2031
- 2026 revenue guidance reduced to $735M-$760M, reflecting iovera° removal after July 31
- UnitedHealthcare separate EXPAREL reimbursement expands access across outpatient settings covering approximately 40M lives
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.